TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8466715

Group type: EXPERIMENTAL
Intervention: 2.5 mg isradipine twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine retard once daily
Number of subjects: 20
Study: 3516078

Group type: EXPERIMENTAL
Intervention: Nebulised beclomethasone dipropionate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 29
Study: 31015270

Group type: EXPERIMENTAL
Intervention: theatre workshop and self-management workshops for children with asthma
Number of subjects: 766
Study: 28734623

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel (n=56)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aspirin plus Placebo (n=57)
Number of subjects: 113
Study: 26571345

Group type: EXPERIMENTAL
Intervention: Iron intake for infants
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Iron intake for toddlers
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Food sources of Fe for infants
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Food sources of Fe for toddlers
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Non-dietary factors associated with Fe intake in infants
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Non-dietary factors associated with Fe intake in toddlers
Number of subjects: 908
Study: 25113132

Group type: EXPERIMENTAL
Intervention: HCV notification
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: HCV-related notification
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: HCV seropositivity testing in prison
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Diagnostic confirmation of HCV infection
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Injecting in prison
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Opioid use
Number of subjects: 735
Study: 21616975

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 19113922

Group type: EXPERIMENTAL
Intervention: Phylloquinone (1 mg daily)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MK4 (45 mg daily)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 17724418

Group type: EXPERIMENTAL
Intervention: Reported pain at discharge
Number of subjects: 169

Group type: COMPARATOR
Intervention: Reported pain vs No pain groups
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Reported pain
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Consistent pain reporting
Number of subjects: 169

Group type: COMPARATOR
Intervention: No pain reporting
Number of subjects: 169
Study: 12544375

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 to 10 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10890026

Group type: EXPERIMENTAL
Intervention: Dietary lycopene
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Serum LDL cholesterol
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Fresh tomatoes or tomato juice
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Cooked tomatoes, tomato sauce, or salsa
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Spaghetti with meat sauce
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 946
Study: 9100582

Group type: EXPERIMENTAL
Intervention: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus salmon calcitonin (100 U/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus placebo
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo plus salmon calcitonin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Combined placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cyclic recombinant human growth hormone plus placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cyclic recombinant human growth hormone plus salmon calcitonin
Number of subjects: 84
Study: 8386794

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally 2‐6 h before surgery)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g intravenously 30‐90 min before surgery)
Number of subjects: 51
Study: 2948534

Group type: COMPARATOR
Intervention: AH23848 (70 mg orally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: AH23848 (70 mg three times a day for seven days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29911511

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions, three interviews per subject, performed monthly over a 3-month period
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 28
Study: 30176974

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 94

Group type: COMPARATOR
Intervention: Upright seated position
Number of subjects: 94
Study: 27177424

Group type: EXPERIMENTAL
Intervention: hfCPR (human feedback)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: mfCPR (mechanical feedback)
Number of subjects: 326

Group type: COMPARATOR
Intervention: sCPR (standard BLS without feedback)
Number of subjects: 326
Study: 24503341

Group type: EXPERIMENTAL
Intervention: 30-minute educational program
Number of subjects: 877

Group type: COMPARATOR
Intervention: Educational brochure
Number of subjects: 877
Study: 22658778

Group type: EXPERIMENTAL
Intervention: Infohealth mobile phone-based intervention
Number of subjects: 700
Study: 20863951

Group type: EXPERIMENTAL
Intervention: varespladib 500 mg daily plus atorvastatin 80 mg daily
Number of subjects: 625

Group type: COMPARATOR
Intervention: placebo plus atorvastatin 80 mg daily
Number of subjects: 625
Study: 18226046

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) at baseline and after 6 years
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Weight increase, waist-to-hip ratio, indices of insulin resistance and beta-cell function
Number of subjects: 910
Study: 15944845

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes
Number of subjects: 209

Group type: COMPARATOR
Intervention: Non-diabetic subjects
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Combined data of both groups
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: C-reactive protein adjusted for BMI
Number of subjects: 209
Study: 12883404

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 45
Study: 10484538

Group type: EXPERIMENTAL
Intervention: Beta-radiation therapy after balloon angioplasty
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (edges of the treated segment)
Number of subjects: 21
Study: 8934779

Group type: EXPERIMENTAL
Intervention: Converted speech rate (1.6 times slower)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Original speech rate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Converted speech rate
Number of subjects: 21
Study: 1860132

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg to 100 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 6311477

Group type: EXPERIMENTAL
Intervention: Enalapril (10, 20, or 40 mg/day for 4 wk each)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30325018

Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: One-legged knee-extensor exercise (single bout)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Single bout of exercise
Number of subjects: 9
Study: 28987245

Group type: EXPERIMENTAL
Intervention: Relaxation classes (four 90-min sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine pregnancy care
Number of subjects: 80
Study: 27491531

Group type: EXPERIMENTAL
Intervention: Guided internet cognitive-behavioural therapy (ICBT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Unguided internet cognitive-behavioural therapy (U-ICBT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Unguided bibliotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition (waiting list)
Number of subjects: 132
Study: 24704281

Group type: EXPERIMENTAL
Intervention: Tooth-borne SARME (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bone-borne SARME (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tooth-borne SARME (n = 13)
Number of subjects: 30
Study: 22971356

Group type: EXPERIMENTAL
Intervention: Intermediate care clinics for diabetes (ICCD)
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Standard GP care (Control)
Number of subjects: 1997
Study: 19389335

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 104
Study: 17564637

Group type: EXPERIMENTAL
Intervention: efalizumab 0.5 mg/kg weekly subcutaneously for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: efalizumab 2 mg/kg weekly subcutaneously for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: efalizumab (both doses)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: efalizumab (higher dose)
Number of subjects: 38
Study: 14643816

Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX) group, 1.5 mg/kg diazoxide infused intravenously within 5 min followed by a 5‐min washout before CPB.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group, time‐matched period of placebo infusion.
Number of subjects: 40
Study: 10480822

Group type: EXPERIMENTAL
Intervention: Intention to treat analysis mentioned in reports
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Exclusion of patients who did not start the allocated intervention
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Analysis of all randomised subjects as allocated
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: No deviations from random allocation
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Analysis according to random allocation
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Missing data on primary outcome variable
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Handling of missing responses
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: More than 10% of responses missing for primary outcome
Number of subjects: 248
Study: 8910173

Group type: EXPERIMENTAL
Intervention: Direct obturator nerve block with 15 ml of lidocaine (Group A, n = 20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bilateral direct obturator nerve block with 30 ml of lidocaine (Group B, n = 12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3‐in‐1 indirect obturator nerve block with 40 ml of lidocaine (Group C, n = 17)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of Groups B and C to Group A
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study: 1676321

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow and peripheral blood stem cells (PBSC)
Number of subjects: 20
Study: 7104161

Group type: EXPERIMENTAL
Intervention: Oral meptazinol (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral meptazinol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral meptazinol (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral meptazinol (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29767467

Group type: EXPERIMENTAL
Intervention: Carboxy therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemical peel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vitamin C mesotherapy
Number of subjects: 45
Study: 28445110

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (HYP; FiO2 0.12, SpO2 82±2%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxia (NOR; FiO2 0.21, SpO2 98±0%)
Number of subjects: 16
Study: 25885012

Group type: COMPARATOR
Intervention: Psychostimulant plus parent training plus placebo (basic treatment)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Psychostimulant plus parent training plus risperidone (augmented treatment)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Responder status
Number of subjects: 150
Study: 24035403

Group type: EXPERIMENTAL
Intervention: LY2140023 (20mg twice daily)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 167
Study: 21926861

Group type: EXPERIMENTAL
Intervention: Protocol B (80 kV with 100 mL of contrast material)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Protocol A (standard 120 kV with 150 mL of contrast material)
Number of subjects: 84
Study: 19194995

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 40-100 mg
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 16505229

Group type: EXPERIMENTAL
Intervention: Mixed meal ingestion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous saline infusion
Number of subjects: 18
Study: 16304280

Group type: EXPERIMENTAL
Intervention: Isotonic histamine challenge
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution challenge
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Hypertonic histamine challenge
Number of subjects: 47
Study: 10598692

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily plus placebo once daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: 2.0% Dorzolamide administered three times daily plus placebo once daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: 0.5% Timolol administered twice daily plus placebo once daily
Number of subjects: 335
Study: 8736372

Group type: EXPERIMENTAL
Intervention: Dermasorb
Number of subjects: 21

Group type: COMPARATOR
Intervention: Jelonet
Number of subjects: 21
Study: 1662636

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg single dose on day 1, followed by 250 mg once-daily on days 2-5)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cefaclor (500 mg t.i.d. for 10 days)
Number of subjects: 119
Study: 6754063

Group type: EXPERIMENTAL
Intervention: Methotrexate with Corynebacterium parvum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study: 31861988

Group type: EXPERIMENTAL
Intervention: Use of treated nets
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Working after dark
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Bathing in a stream after dark
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Collecting water after dark
Number of subjects: 175
Study: 29433850

Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg)
Number of subjects: 954

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice-daily in 28-day cycles)
Number of subjects: 954
Study: 25968450

Group type: EXPERIMENTAL
Intervention: Sympathetic Skin Response (SSR) assessment in CLBP and FBSS patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain intensity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI) for perceived functional disability
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electrophysiologic nerve conduction studies
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 40
Study: 24875610

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1030
Study: 22989921

Group type: EXPERIMENTAL
Intervention: Short duration of untreated negative symptoms (DUNS)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Short duration of untreated positive symptoms (DUPS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Long duration of untreated symptoms
Number of subjects: 77
Study: 20430379

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long protocol (control)
Number of subjects: 0
Study: 17919718

Group type: EXPERIMENTAL
Intervention: Combined cytological and HPV DNA testing
Number of subjects: 17155

Group type: COMPARATOR
Intervention: Conventional cytological testing only
Number of subjects: 17155
Study: 16264400

Group type: EXPERIMENTAL
Intervention: Oxytocinase plasma activity measured in pregnant women a few days before delivery.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RCAS1 expression assessment by Western blot analysis.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Assessment of RCAS1 in placenta directly after delivery.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Level of immune tolerance at the moment of delivery.
Number of subjects: 160
Study: 11899964

Group type: EXPERIMENTAL
Intervention: Cr supplements as brewer's yeast
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cr supplements as CrCl3
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cr supplements (both types)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Subjects responding to Cr supplement
Number of subjects: 78
Study: 10078403

Group type: EXPERIMENTAL
Intervention: Low dose mivacurium (0.08 mg.kg‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low dose succinylcholine (0.5 mg.kg‐1)
Number of subjects: 16
Study: 7723664

Group type: EXPERIMENTAL
Intervention: Overnight branched-chain amino acid (BCAA) infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 2143459

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 44
Study: 31040207

Group type: EXPERIMENTAL
Intervention: HFNC + DTM
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HFNC + DTM (in responders)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HFNC alone
Number of subjects: 15
Study: 28475619

Group type: EXPERIMENTAL
Intervention: Joint condition (actors sharing a goal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parallel condition (actors acting alone)
Number of subjects: 0
Study: 26329358

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 121

Group type: COMPARATOR
Intervention: Rapid shallow breathing index (RSBI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Maximum inspiratory pressure
Number of subjects: 121

Group type: COMPARATOR
Intervention: RSBI at 1 min (RSBI1)
Number of subjects: 121

Group type: COMPARATOR
Intervention: RSBI at 30 min (RSBI30)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Absolute percentage change in RSBI from 1 to 30 min (ΔRSBI30)
Number of subjects: 121
Study: 23782681

Group type: EXPERIMENTAL
Intervention: Thrombectomy (thrombus aspiration)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention (PCI) alone
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Thrombectomy and PCI
Number of subjects: 460
Study: 21724263

Group type: EXPERIMENTAL
Intervention: Intravitreal 1.25 mg/0.05 ml bevacizumab injection 1 to 14 days before PPV (Group 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravitreal 1.25 mg/0.05 ml bevacizumab injection at the end of PPV (Group 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No IVB injection (Group 3)
Number of subjects: 91
Study: 19367173

Group type: EXPERIMENTAL
Intervention: EXPLORE intervention
Number of subjects: 4295
Study: 18173006

Group type: EXPERIMENTAL
Intervention: Lactofem (1 capsule and 2 ml of gel every third day for one month)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lactofem (for asymptomatic BV)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Metronidazole (1 g daily for 7 days)
Number of subjects: 55
Study: 14716182

Group type: EXPERIMENTAL
Intervention: Intravaginal estriol (1 mg once daily for 2 weeks, then 2 ovules once weekly for 6 months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intravaginal estriol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Inert placebo vaginal suppositories
Number of subjects: 88
Study: 11549632

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg twice daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 9506322

Group type: EXPERIMENTAL
Intervention: 8-week intensive exercise program (two 1-hour walking sessions per day and four 40-minute bicycle ergometer training sessions at 70% to 80% peak exercise capacity per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sedentary life at home for 8 weeks
Number of subjects: 25
Study: 7509244

Group type: EXPERIMENTAL
Intervention: Acetorphan (300 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3044506

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms (one puff) given twice daily during 6-week treatment period
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (one puff) given twice daily during 6-week control period
Number of subjects: 39
Study: 30277997

Group type: EXPERIMENTAL
Intervention: Porous titanium coating (PTC)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Plasma-sprayed titanium (PS)
Number of subjects: 380
Study: 28693456

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1000
Study: 26267453

Group type: EXPERIMENTAL
Intervention: Culturally Appropriate Hypertension Education (CAHE)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 139
Study: 23152035

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 76
Study: 21958782

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 20
Study: 18328363

Group type: EXPERIMENTAL
Intervention: Low-amount-high-intensity aerobic exercise training
Number of subjects: 189